Marc Soco, MD

Kidney injury occuring in liver failure is a historical scenario imbued w/in the parlance of medicine for centuries. In this article, I try to discuss HRS— its current concepts & challenges. Thank you @Nephro_Sparks @DearbhlaKelly4 for helping me write this article!

2/ @brian_rifkin 's recap highlighted our progress and future plans, but what stays with me is this: #nephjc never stops adapting. We keep learning, improving, and reaching for a better version of ourselves 🌟

1/ Today’s #nephjc graduation was pure joy. Seeing mentors and interns from around the world come together reminded me why this community matters. ✨Thank you for making it extraordinary @hswapnil @Nephro_Sparks @salinesalut @FravelShellie @meyyappannephro @roxnonna23

Delighted that FIND CKD has meet its primary endpoint. Fantastic news for patients with non-diabetic CKD, including those with GNs, including IgAN Thank you to Bayer, all the investigators, study teams & patients who have made FIND-CKD possible bayer.com/media/en-us/fi…

Proactive vs Reactive DDAVP: The Clamp Finally Faces an RCT Thank you Thai Air Force for doing the trials that need to be done! pbfluids.com/2026/03/proact…

New terminology for iron deficiency in CKD ca. 2026 from @goKDIGO #Nephpearls Systemic iron deficiency (previously Absolute iron deficiency) ⬇️ Ferritin ⬇️ TSAT​ Iron-restricted erythropoiesis (previously Functional iron deficiency) ⬆️ Ferritin ⬇️ TSAT​ 👉 kdigo.org/guidelines/ane…

Simultaneous initiation of finerenone and empagliflozin was effective and well tolerated among CONFIDENCE study participants from Asia, consistent with the overall population ca. 2026 from @asnpublications #Nephpearls 👉 pubmed.ncbi.nlm.nih.gov/40965042/

Simultaneous initiation of finerenone and empagliflozin was effective and well tolerated among CONFIDENCE study participants from Asia, consistent with the overall population ca. 2026 from @asnpublications #Nephpearls 👉 pubmed.ncbi.nlm.nih.gov/40965042/

Checkout the VA for our next discussion on INFINITI, SGLT2i use in transplant patients. #NephTwitter nephjc.com/news/2026/2/8/…

🍌🥑Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? 🎨 #Visualabstract by @meyyappannephro ⏰ #NephJC chat on Jan 27, 9 pm EST nephjc.com/news/2026/1/25…

Check out the VA for VALIANT by @DrAkshayaJ #NephJC nephjc.com/news/2026/1/11…

It's 2026!🎉 We will be counting down the Top Ten Nephrology Stories of 2025 on 1/6/26 at 9 pm EST. Join us on TWITTER (yes, it will always be Twitter to us). Come on by #NephJC faithful for a lively discussion! You picked & we're count'em down. nephjc.com/news/2025/1/3/…

What’s the default mood of @uppghnephrology Renal Fellows when referrals are nonstop? PISSED 😒😂

The end of an era. @BookBurton

Join us for the last #NephJC of 2025!🥳🪩 We're all for freedom ⛓️, but how soon should we withhold dialysis in AKI. We're discussing the LIBERATE-D trial #NephTwitter This one might just change your mind 🧠🧠 blog by @msocoMD and @sejalplakhani nephjc.com/news/liberated…

Holy Mackerel! 🐟 Could fish oil unlock the mysteries of increased CV mortality in ESRD?🏴‍☠️ Check out the PISCES VA by @brian_rifkin nephjc.com/news/piscesva

1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC Read the @NEJM article 👇 nejm.org/doi/10.1056/NE…

Succession...#NephJC Style nephjc.com/news/2025/11/2…

Check out the awesome visual abstract by @salinesolut Attacking the origins of IgAN with atacicept ⚔️ nephjc.com/news/2025/11/1…

Tonite 11/18/25 on #Bluesky 9pm EST We are discussing ORIGIN3 and atacicept in IgAN. APRIL/BAFF and B-cells, Oh My! (🦁🐯🐻) It's going to be Wicked good. 🧙‍♀️#NephJC nephjc.com/news/atacicept…

Now online in @NDTsocial Efficacy and safety of finerenone with SGLT2i in IgAN 🧐 Fin-SGLT2i therapy showed superior proteinuria reduction versus monotherapy in IgAN, with preserved kidney function and good safety. ▶️ academic.oup.com/ndt/article-ab…